Navigation Links
LA BioMed's Dr. John Tsuang examines effects of Ibudilast and metamphetamines
Date:4/25/2012

LOS ANGELES (April 25, 2012) John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine. Ibudilast is a non-selective phosphodiesterase inhibitor known as a modulator of glial activation in the central nervous system; the role of these glial cells is to regulate the repair of neurons after an injury, such as the neurocognitive deficits caused by long-term MA addiction. The study is being funded by the National Institutes of Health National Institute on Drug Abuse (NIDA).

More commonly known as "speed," "meth" or "ice," MA is long lasting and toxic to dopamine nerve terminals in the central nervous system (NIDA). According to the Substance Abuse and Mental Health Services Administration (SAMHSA), a 2009 survey revealed that 1.2 million Americans ages 12 and older had abused MA at least once prior to the year they were surveyed. According to the SAMHSA, MA dependence causes devastating personal and public health consequences, particularly in the Western and Midwestern United States.

"Currently, there are no approved medications to help treat MA dependence," said Dr. Tsuang. "Through this study, we are working to determine the effects of Ibudilast - combined with relevant doses of MA - on heart rate and blood pressure, and whether or not Ibudilast alters the way in which the body absorbs, distributes, and metabolizes MA. The development of one or more medications to reduce MA abuse, when implemented with evidence-based behavioral and counseling interventions, would have obvious public health significance."

Dr. Tsuang and his colleagues are utilizing a randomized double-blind, placebo-controlled within-subject crossover design to determine the safety and tolerability and subjective and reinforcing effects of MA in 12 participants who are not seeking treatment for MA dependence. The participants will be treated with oral Ibudilast (20mg BID and 50mg BID) and placebo.

Recent research suggests that glial cells may be important in modulating the rewarding properties of drugs that are abused, including MA. Research also suggests that MA-induced glial activation may help reduce the damage done to the central nervous system and associated cognitive dysfunction via glial cell secretion of pro-inflammatory cytokines, which are proteins that interact with cells of the immune system in order to regulate the body's response to disease and infection.

Dr. Tsuang is hoping that following the initial safety trial, physicians will be able to utilize Ibudilast in treating patients with MA dependence to help them improve memory and reduce the damage done to their central nervous system due to MA abuse.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. Ming T. Tsuang recognized with NARSAD outstanding achievement award for schizophrenia research
2. New Research Examines Impact of Health Care Reform on Regional Health Plans
3. New national study examines weight training-related injuries
4. Cedars-Sinai study examines regional use of minimally invasive repair of aneurysms
5. AERA journal examines research issues
6. CWRU study examines effectiveness of telemonitoring vital signs
7. AP-CNBC Poll Examines "Marijuana & Money"
8. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
9. Study examines global availability of treatment involving transplantation of blood stem cells
10. Wednesday, May 26: Forum Examines State of Literacy In Connecticut
11. UAB study examines hearing loss, Viagra use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... spark a conversation on the current obstacles facing infection prevention and offer strategies ... deaths caused by these infections. , The print component of “Fighting Infection” ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in Southlake, ... leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” ... designed to teach how to maximize their sales efforts, as well as how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... conjugates market has been growing rapidly as the global sales of ... Globally, the growth in the antibody drug conjugates market is driven ... incidences of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and ...
(Date:3/24/2017)... 2017  GenomeDx Biosciences today announced that six abstracts ... Prostate Cancer Classifier tests will be presented at the ... Congress held March 24 to 28, 2017 in ... is Europe,s largest urological event ... urological field. The abstract titled "Muscle invasive ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
Breaking Medicine Technology: